AD/PD 2026: Novo Nordisk’s semaglutide fails to demonstrate any benefit for early Alzheimer’s
On March 19, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, during a …
Post
-
-
Roche drops Phase III plans for emugrobart in two muscle wasting diseases
Roche has halted plans to progress its anti-myostatin antibody, emugrobart, to Phase III trials in spinal muscular atrophy (SMA) and …
-
Greenwich adds City of Hope to FLAMINGO-01 trial for breast cancer
Greenwich LifeSciences has added City of Hope to its Phase III FLAMINGO-01 clinical trial, which is investigating the GLSI-100 immunotherapy …
-
Shionogi enrols first patients in Esprit trial for Pompe disease
Shionogi has enrolled the first patients in its global Phase II clinical trial, Esprit, assessing the investigational drug S-606001 in …
-
FDA outlines plan to phase out animal testing in new draft guidance
The US Food and Drug Administration (FDA) has advanced its plan to phase out animal testing by debuting draft guidance …
-
TB or not TB: WHO releases new TB diagnostic guidelines ahead of World TB Day
World Tuberculosis Day will be celebrated on 24 March, and new recommendations for tuberculosis (TB) diagnostic techniques from the World …
-
Lilly’s triple G agonist succeeds in Phase III diabetes trial
Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone receptor agonist has met its primary endpoints in …
-
Aspen’s personalised Parkinson’s cell therapy to advance to Phase III
Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF" …
-
Population patterns of CKD: the role of age and sex
World Kidney Day, observed each year in March, draws attention to the global burden of kidney disease and the importance …
-
Silent spread, serious consequences: the shifting trends of AMR
Antimicrobial resistance (AMR) occurs when bacteria change in ways that make antibiotics less effective. As a result, infections that were …
-
Kidney disease risk higher after Covid infection than after influenza infection
Covid-19 has been associated with an increased risk of a variety of disorders, including cardiovascular disease, clotting disorders, diabetes, chronic …
-
Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer
Pfizer’s oral cyclin-dependent kinase 4 (CDK4) inhibitor, atirmociclib, has met the primary endpoint in a Phase II trial as a …
-
PhaseV unveils centralised platform to automate clinical trials
PhaseV has launched the AI Conductor centralised platform designed to automate every stage in the clinical trial process from drafting protocols …
-
START and Trialing collaborate on oncology clinical trials
The START Center for Cancer Research (START) has entered a partnership with Trialing, aimed at increasing oncology clinical trial access …
-
CellProthera sets the scene for Phase III stem cell therapy trial
CellProthera is set to begin a Phase III study exploring the potential of its stem cell therapy in patients with …
